Kairos Pharma Ltd (KAPA)

$0.83 +0.04 (4.85%)
Market Cap 17.21M
Revenue (ttm) 0.00
Net Income (ttm) -2.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 428,000
Avg Vol 754,134
Day's Range N/A - N/A
Shares Out 20.74M
Stochastic %K 40%
Beta 2.02
Analysts Strong Sell
Price Target $8.33

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology
Sector: Healthcare
Phone: 310-948-2356
Address:
2355 Westwood Boulevard, Suite 139, Los Angeles, United States
Xtracked
Xtracked Nov. 16 at 11:42 AM
$KAPA
0 · Reply
stockforce123
stockforce123 Nov. 14 at 7:35 PM
$KAPA Lonza commented on the production of TRC105 (Now ENV105):"“This is our first batch of Carotuximab (ENV105) from the single use facility with a view to fulfilling their needs for global commercial supply as they move towards approval,” said Wheat.
0 · Reply
stockforce123
stockforce123 Nov. 14 at 7:24 PM
$KAPA The reactivation of Lonza mass production of ENV105 with Kairos Pharma confirms major partnership has been formed with Kairos Pharma for the upcoming later-state clinical trials!
1 · Reply
stockforce123
stockforce123 Nov. 14 at 7:20 PM
$KAPA Lonza has been the manufacturing partner for carotuximab since its early development phases! In 2018, Lonza produced the first 2,000 L batch of Tracon Pharmaceuticals’ antibody TRC105 from its Singapore facility after transferring production from the UK. Now TRC105 is Kairos Pharma's new ENV105! They are now officially start rolling on mass production of this drug!!!
0 · Reply
stockforce123
stockforce123 Nov. 14 at 7:11 PM
$KAPA Kairos Pharma singed contract with Lonza AG in Switzerland, the world’s largest contract drug development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry, in November 2025! It has started rolling! Exhibit 10.3: https://d18rn0p25nwr6d.cloudfront.net/CIK-0001962011/3683e1b5-d6ac-4c3f-9d5d-438e0faa9688.pdf https://www.lonza.com "Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. We work alongside a broad range of customers – from emerging biotechs to global pharmaceutical companies – to transform their therapeutic discoveries into life-saving and life-enhancing treatments for their patients. "
0 · Reply
StrawberryRips
StrawberryRips Nov. 14 at 6:48 PM
$KAPA there it was 👀
0 · Reply
stockforce123
stockforce123 Nov. 14 at 6:46 PM
$KAPA 10Q was just filed
0 · Reply
stockforce123
stockforce123 Nov. 14 at 1:44 AM
$KAPA 10Q tomorrow
0 · Reply
brclyr
brclyr Nov. 12 at 11:57 PM
$KAPA
0 · Reply
Xtracked
Xtracked Nov. 12 at 11:55 PM
$KAPA You are a fool if you are not holding this ... Deal is closed IMO... supporters will be rewarded:) **PR any day now**
2 · Reply
Latest News on KAPA
Kairos Pharma Provides Shareholder Update

Nov 4, 2025, 8:00 AM EST - 12 days ago

Kairos Pharma Provides Shareholder Update

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Oct 20, 2025, 8:00 AM EDT - 27 days ago

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Oct 7, 2025, 8:00 AM EDT - 5 weeks ago

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Sep 18, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 11, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 3, 2025, 8:15 AM EDT - 2 months ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 2 months ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 28, 2025, 12:28 PM EDT - 3 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 16, 2025, 8:30 AM EDT - 4 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Why Is Kairos Pharma Stock Surging On Tuesday?

Jul 15, 2025, 2:08 PM EDT - 4 months ago

Why Is Kairos Pharma Stock Surging On Tuesday?

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jul 15, 2025, 8:00 AM EDT - 4 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Jun 3, 2025, 8:15 AM EDT - 5 months ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma, Ltd. Announces Participation in the D.

May 6, 2025, 8:00 AM EDT - 6 months ago

Kairos Pharma, Ltd. Announces Participation in the D.

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 24, 2025, 8:00 AM EDT - 7 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Apr 17, 2025, 8:00 AM EDT - 7 months ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 27, 2025, 4:05 PM EDT - 8 months ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Mar 20, 2025, 7:30 AM EDT - 8 months ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 26, 2025, 7:00 AM EST - 9 months ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 18, 2025, 8:30 AM EST - 9 months ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 11, 2025, 8:30 AM EST - 9 months ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Feb 6, 2025, 8:30 AM EST - 10 months ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 28, 2025, 8:15 AM EST - 10 months ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 21, 2025, 8:30 AM EST - 10 months ago

Kairos Pharma Provides Business Update and Outlook into 2025

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Jan 7, 2025, 8:15 AM EST - 11 months ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Dec 26, 2024, 7:51 AM EST - 11 months ago

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 16, 2024, 12:15 PM EST - 11 months ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Dec 3, 2024, 8:30 AM EST - 1 year ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

IBN Initiates Coverage of Kairos Pharma Ltd.

Nov 26, 2024, 8:30 AM EST - 1 year ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

Sep 21, 2024, 2:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

BIOA BKV FBGL GLE GRDN LGCY PRB

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Kairos Pharma Prices $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Feb 14, 2024, 6:16 PM EST - 1 year ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Kairos Pharma Files For U.S. IPO

Oct 3, 2023, 3:33 PM EDT - 2 years ago

Kairos Pharma Files For U.S. IPO

Xtracked
Xtracked Nov. 16 at 11:42 AM
$KAPA
0 · Reply
stockforce123
stockforce123 Nov. 14 at 7:35 PM
$KAPA Lonza commented on the production of TRC105 (Now ENV105):"“This is our first batch of Carotuximab (ENV105) from the single use facility with a view to fulfilling their needs for global commercial supply as they move towards approval,” said Wheat.
0 · Reply
stockforce123
stockforce123 Nov. 14 at 7:24 PM
$KAPA The reactivation of Lonza mass production of ENV105 with Kairos Pharma confirms major partnership has been formed with Kairos Pharma for the upcoming later-state clinical trials!
1 · Reply
stockforce123
stockforce123 Nov. 14 at 7:20 PM
$KAPA Lonza has been the manufacturing partner for carotuximab since its early development phases! In 2018, Lonza produced the first 2,000 L batch of Tracon Pharmaceuticals’ antibody TRC105 from its Singapore facility after transferring production from the UK. Now TRC105 is Kairos Pharma's new ENV105! They are now officially start rolling on mass production of this drug!!!
0 · Reply
stockforce123
stockforce123 Nov. 14 at 7:11 PM
$KAPA Kairos Pharma singed contract with Lonza AG in Switzerland, the world’s largest contract drug development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry, in November 2025! It has started rolling! Exhibit 10.3: https://d18rn0p25nwr6d.cloudfront.net/CIK-0001962011/3683e1b5-d6ac-4c3f-9d5d-438e0faa9688.pdf https://www.lonza.com "Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. We work alongside a broad range of customers – from emerging biotechs to global pharmaceutical companies – to transform their therapeutic discoveries into life-saving and life-enhancing treatments for their patients. "
0 · Reply
StrawberryRips
StrawberryRips Nov. 14 at 6:48 PM
$KAPA there it was 👀
0 · Reply
stockforce123
stockforce123 Nov. 14 at 6:46 PM
$KAPA 10Q was just filed
0 · Reply
stockforce123
stockforce123 Nov. 14 at 1:44 AM
$KAPA 10Q tomorrow
0 · Reply
brclyr
brclyr Nov. 12 at 11:57 PM
$KAPA
0 · Reply
Xtracked
Xtracked Nov. 12 at 11:55 PM
$KAPA You are a fool if you are not holding this ... Deal is closed IMO... supporters will be rewarded:) **PR any day now**
2 · Reply
GIPARK
GIPARK Nov. 12 at 11:39 PM
$KAPA 언제오르냐 하
0 · Reply
stockforce123
stockforce123 Nov. 11 at 11:58 PM
$KAPA Kairos time coming
1 · Reply
Dvsjes2800
Dvsjes2800 Nov. 11 at 8:23 PM
$KAPA holding on!
0 · Reply
ezcheezie
ezcheezie Nov. 7 at 4:05 PM
$KAPA I love when I get to buy shares on sale. Load up now, earnings call is coming fast.
0 · Reply
StrawberryRips
StrawberryRips Nov. 6 at 11:47 PM
$KAPA gap down to low .70s is a good buy zone.
0 · Reply
TrdrBuckNKy
TrdrBuckNKy Nov. 6 at 8:10 PM
$KAPA ....second the motion!
0 · Reply
ChrisBAB
ChrisBAB Nov. 6 at 5:57 PM
$KAPA Added more!
0 · Reply
Landomos
Landomos Nov. 6 at 12:37 AM
$KAPA
0 · Reply
SPYmyQQQ
SPYmyQQQ Nov. 5 at 2:02 PM
🚀 New Signal ✅ 💊 $KAPA 🗓️ Nov 5, 2025 💵 Entry: $0.9100 🎯 Target (Opt.): $1.08 (+18.66%) 👉 FREE TRIAL! Check bio.
0 · Reply
Xtracked
Xtracked Nov. 5 at 1:31 PM
$KAPA Please clarify your meaning of selected internally... Thanks
1 · Reply
jai105
jai105 Nov. 5 at 12:36 PM
$KAPA Kairos Pharma (NYSE: KAPA) has revealed positive interim efficacy data from its Phase 2 trial of ENV-105 for metastatic castration-resistant prostate cancer (mCRPC). The findings, presented at the European Society for Medical Oncology (ESMO) meeting, suggest a significant clinical benefit when ENV-105, a CD105 antagonist, is combined with the standard therapy apalutamide.
0 · Reply
stockforce123
stockforce123 Nov. 5 at 8:10 AM
$KAPA Knock knock - "We continue to feel confident in the paradigm-shifting potential of our therapeutics, which are based on the breakthrough science developed by our officers. We believe these therapeutics will show the potential to make a lasting impact by stopping the relentless spread of human neoplastic disorders (cancer tumors)."
0 · Reply